September 2011 · Vol. 60, No. 09: 518-523Aspirin for CV prevention—for which patients?
Put your patient on aspirin? Take him off? Here’s what you need to know to get it right.
Anita
N.
Jackson,
PharmDUniversity of Rhode Island College of Pharmacy, Kingston
anitaj@uri.edu Anne
L.
Hume,
PharmD, FCCP, BCPSUniversity of Rhode Island College of Pharmacy, Kingston, Memorial Hospital, Department of Family Medicine, Pawtucket, RI
|
PRACTICE RECOMMENDATIONS
• Calculate a patient’s 10-year global risk of cardiovascular events using a risk-assessment tool before recommending aspirin for primary prevention. A
• Keep in mind that diabetes is not an indication for aspirin as primary cardiovascular protection, unless the patient’s calculated 10-year risk is >10%. A
Strength of recommendation (SOR)
A Good-quality patient-oriented evidence
B Inconsistent or limited-quality patient-oriented evidence
C Consensus, usual practice, opinion, disease-oriented evidence, case series
|
The authors reported no potential conflict of interest relevant to this article.
Among individuals at high risk (≥10%) for coronary heart disease (CHD) within 10 years, only 44% are taking aspirin.1 In addition, for patients at high risk for CHD events, estimated aspirin use varies among ethnic groups: 53% for whites, 43% for African Americans, 38% for Hispanics, and 28% for Chinese Americans.1
|
